(Date:5/22/2013)... , May 22, 2013 Pomerantz ... investigating claims on behalf of investors of Intuitive Surgical, ... ISRG ) (CUSIP: 46120E602) who purchased Intuitive Surgical common ... (the "Class Period"). Such investors are advised to contact ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ...
(Date:5/22/2013)... Minn. , May 22, 2013 /PRNewswire/ ... the successful completion of its global Phase ... an internally developed program for the management ... proprietary formulation technology. USL255 is specifically engineered ... fluctuations in topiramate blood levels observed with ...
(Date:5/22/2013)... Mass. and TORONTO , ... ) (OTCBB: GNBT) today announced three presentations demonstrating the ... by its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ... meeting of the American Society of Clinical Oncology (ASCO) ... from May 31 through June 4, 2013. ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4